Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

Authors: Enrico P Spugnini, Alfonso Baldi, Sabrina Buglioni, Francesca Carocci, Giulia Milesi de Bazzichini, Gianluca Betti, Ilaria Pantaleo, Francesco Menicagli, Gennaro Citro, Stefano Fais

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient mechanism of tumor resistance to drugs is related to the modification of tumour microenvironment through changes in the extracellular and intracellular pH. The acidification of tumor microenvironment depends on proton pumps that actively pump protons outside the cells, mostly to avoid intracellular acidification. In fact, we have shown in pre-clinical settings as pre-treatment with proton-pumps inhibitors (PPI) increase tumor cell and tumor responsiveness to chemotherapeutics. In this study pet with spontaneously occurring cancer proven refractory to conventional chemotherapy have been recruited in a compassionate study.

Methods

Thirty-four companion animals (27 dogs and 7 cats) were treated adding to their chemotherapy protocols the pump inhibitor lansoprazole at high dose, as suggested by pre-clinical experiments. Their responses have been compared to those of seventeen pets (10 dogs and 7 cats) whose owners did not pursue any other therapy than continuing the currently ongoing chemotherapy protocols.

Results

The drug was overall well tolerated, with only four dogs experiencing side effects due to gastric hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response twenty-three pets out of 34 had partial or complete responses (67.6%) the remaining patients experienced no response or progressive disease however most owners reported improved quality of life in most of the non responders. On the other hand, only three animals in the control group (17%) experienced short lived partial responses (1-3 months duration) while all the others died of progressive disease within two months.

Conclusions

high dose proton pump inhibitors have been shown to induce reversal of tumor chemoresistance as well as improvement of the quality of life in pets with down staged cancer and in the majority of the treated animals PPI were well tolerated. Further studies are warranted to assess the efficacy of this strategy in patients with advanced cancers in companion animals as well as in humans.
Appendix
Available only for authorised users
Literature
2.
go back to reference Forgac M: Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007, 8: 917-929. 10.1038/nrm2272.CrossRefPubMed Forgac M: Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007, 8: 917-929. 10.1038/nrm2272.CrossRefPubMed
3.
go back to reference Cipriano DJ, Wang Y, Bond S, Hinton A, Jefferies KC, Qi J, Forgac M: Structure and regulation of the vacuolar ATPases. Biochim Biophys Acta. 2008, 1777: 599-604. 10.1016/j.bbabio.2008.03.013.PubMedCentralCrossRefPubMed Cipriano DJ, Wang Y, Bond S, Hinton A, Jefferies KC, Qi J, Forgac M: Structure and regulation of the vacuolar ATPases. Biochim Biophys Acta. 2008, 1777: 599-604. 10.1016/j.bbabio.2008.03.013.PubMedCentralCrossRefPubMed
4.
go back to reference Jefferies KC, Cipriano DJ, Forgac M: Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008, 476: 33-42. 10.1016/j.abb.2008.03.025.PubMedCentralCrossRefPubMed Jefferies KC, Cipriano DJ, Forgac M: Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008, 476: 33-42. 10.1016/j.abb.2008.03.025.PubMedCentralCrossRefPubMed
5.
go back to reference Sautin YY, Lu M, Gaugler A, Zhang L, Gluck SL: Phosphatidylinositol 3-kinase-mediated effects of glucose on vacuolar H+-ATPase assembly, translocation, and acidification of intracellular compartments in renal epithelial cells. Mol Cell Biol. 2005, 25: 575-589. 10.1128/MCB.25.2.575-589.2005.PubMedCentralCrossRefPubMed Sautin YY, Lu M, Gaugler A, Zhang L, Gluck SL: Phosphatidylinositol 3-kinase-mediated effects of glucose on vacuolar H+-ATPase assembly, translocation, and acidification of intracellular compartments in renal epithelial cells. Mol Cell Biol. 2005, 25: 575-589. 10.1128/MCB.25.2.575-589.2005.PubMedCentralCrossRefPubMed
6.
go back to reference Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I: Activation of lysosomal function during dendritic cell maturation. Science. 2003, 299: 1400-1403. 10.1126/science.1080106.CrossRefPubMed Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I: Activation of lysosomal function during dendritic cell maturation. Science. 2003, 299: 1400-1403. 10.1126/science.1080106.CrossRefPubMed
7.
go back to reference Feng Y, Forgac M: A novel mechanism for regulation of vacuolar acidification. J Biol Chem. 1992, 267: 19769-19772.PubMed Feng Y, Forgac M: A novel mechanism for regulation of vacuolar acidification. J Biol Chem. 1992, 267: 19769-19772.PubMed
8.
go back to reference Feng Y, Forgac M: Cysteine 254 of the 73-kDa A subunit is responsible for inhibition of the coated vesicle (H+)-ATPase upon modification by sulfhydryl reagents. J Biol Chem. 1992, 267: 5817-5822.PubMed Feng Y, Forgac M: Cysteine 254 of the 73-kDa A subunit is responsible for inhibition of the coated vesicle (H+)-ATPase upon modification by sulfhydryl reagents. J Biol Chem. 1992, 267: 5817-5822.PubMed
9.
go back to reference Feng Y, Forgac M: Inhibition of vacuolar H(+)-ATPase by disulfide bond formation between cysteine 254 and cysteine 532 in subunit A. J Biol Chem. 1994, 269: 13224-13230.PubMed Feng Y, Forgac M: Inhibition of vacuolar H(+)-ATPase by disulfide bond formation between cysteine 254 and cysteine 532 in subunit A. J Biol Chem. 1994, 269: 13224-13230.PubMed
10.
go back to reference Forgac M: The vacuolar H+-ATPase of clathrin-coated vesicles is reversibly inhibited by Snitrosoglutathione. J Biol Chem. 1999, 274: 301-1305. Forgac M: The vacuolar H+-ATPase of clathrin-coated vesicles is reversibly inhibited by Snitrosoglutathione. J Biol Chem. 1999, 274: 301-1305.
11.
go back to reference Xu T, Forgac M: Subunit D (Vma8p) of the yeast vacuolar H+-ATPase plays a role in coupling of proton transport and ATP hydrolysis. J Biol Chem. 2000, 275: 22075-22081. 10.1074/jbc.M002983200.CrossRefPubMed Xu T, Forgac M: Subunit D (Vma8p) of the yeast vacuolar H+-ATPase plays a role in coupling of proton transport and ATP hydrolysis. J Biol Chem. 2000, 275: 22075-22081. 10.1074/jbc.M002983200.CrossRefPubMed
12.
go back to reference Kawasaki-Nishi S, Bowers K, Nishi T, Forgac M, Stevens TH: The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis. J Biol Chem. 2001, 276: 47411-47420. 10.1074/jbc.M108310200.CrossRefPubMed Kawasaki-Nishi S, Bowers K, Nishi T, Forgac M, Stevens TH: The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis. J Biol Chem. 2001, 276: 47411-47420. 10.1074/jbc.M108310200.CrossRefPubMed
13.
go back to reference Saitoh O, Wang WC, Lotan R, Fukuda M: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1992, 267: 5700-5711.PubMed Saitoh O, Wang WC, Lotan R, Fukuda M: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1992, 267: 5700-5711.PubMed
14.
go back to reference Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM: Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia. 2003, 5: 533-545.PubMedCentralCrossRefPubMed Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM: Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia. 2003, 5: 533-545.PubMedCentralCrossRefPubMed
15.
go back to reference Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4: 891-899. 10.1038/nrc1478.CrossRefPubMed Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4: 891-899. 10.1038/nrc1478.CrossRefPubMed
16.
go back to reference Fais S, De Milito A, You H, Qin W: Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007, 67: 10627-10630. 10.1158/0008-5472.CAN-07-1805.CrossRefPubMed Fais S, De Milito A, You H, Qin W: Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007, 67: 10627-10630. 10.1158/0008-5472.CAN-07-1805.CrossRefPubMed
17.
go back to reference Nishi T, Forgac M: The vacuolar (H+)-ATPases nature's most versatile proton pumps. Nat Rev Mol Cell Biol. 2002, 3: 94-103. 10.1038/nrm729.CrossRefPubMed Nishi T, Forgac M: The vacuolar (H+)-ATPases nature's most versatile proton pumps. Nat Rev Mol Cell Biol. 2002, 3: 94-103. 10.1038/nrm729.CrossRefPubMed
18.
go back to reference Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ: Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol. 1993, 265: 1015-29. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ: Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol. 1993, 265: 1015-29.
19.
go back to reference Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S: The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 2005, 65: 6843-6849. 10.1158/0008-5472.CAN-04-3822.CrossRefPubMed Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S: The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 2005, 65: 6843-6849. 10.1158/0008-5472.CAN-04-3822.CrossRefPubMed
20.
go back to reference Mahoney BP, Raghunand N, Bagget B, Gillies RJ: Tumor acidity, ione trapping and chemotherapeutics I. Acid pH effects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003, 66: 1207-1218. 10.1016/S0006-2952(03)00467-2.CrossRefPubMed Mahoney BP, Raghunand N, Bagget B, Gillies RJ: Tumor acidity, ione trapping and chemotherapeutics I. Acid pH effects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003, 66: 1207-1218. 10.1016/S0006-2952(03)00467-2.CrossRefPubMed
21.
go back to reference Simon S, Roy D, Schindler M: Intracellular Ph and the control of multidrug resistance. Proc Nat Acad Sci USA. 1993, 91: 1128-1132.CrossRef Simon S, Roy D, Schindler M: Intracellular Ph and the control of multidrug resistance. Proc Nat Acad Sci USA. 1993, 91: 1128-1132.CrossRef
22.
go back to reference Raghunand N, Mahoney BP, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. BiochemPharmacol. 2003, 66: 1219-1229. Raghunand N, Mahoney BP, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. BiochemPharmacol. 2003, 66: 1219-1229.
23.
go back to reference Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ: pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999, 57: 1037-1046. 10.1016/S0006-2952(99)00022-2.CrossRefPubMed Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ: pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999, 57: 1037-1046. 10.1016/S0006-2952(99)00022-2.CrossRefPubMed
24.
go back to reference Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ: pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol. 1999, 57: 1047-1058. 10.1016/S0006-2952(99)00021-0.CrossRefPubMed Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ: pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol. 1999, 57: 1047-1058. 10.1016/S0006-2952(99)00021-0.CrossRefPubMed
25.
go back to reference Bobichon H, Colin M, Depierreux C, Liautaud-Roger F, Jardillier JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J Exp Ther Oncol. 1996, 1: 49-61.PubMed Bobichon H, Colin M, Depierreux C, Liautaud-Roger F, Jardillier JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J Exp Ther Oncol. 1996, 1: 49-61.PubMed
26.
go back to reference Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004, 96: 1702-1713. 10.1093/jnci/djh305.CrossRefPubMed Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004, 96: 1702-1713. 10.1093/jnci/djh305.CrossRefPubMed
27.
go back to reference De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S: pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010, 127: 207-19. 10.1002/ijc.25009.CrossRefPubMed De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S: pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010, 127: 207-19. 10.1002/ijc.25009.CrossRefPubMed
28.
go back to reference Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K: Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 2001, 93: 869-874. 10.1002/ijc.1418.CrossRefPubMed Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K: Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 2001, 93: 869-874. 10.1002/ijc.1418.CrossRefPubMed
29.
go back to reference Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K: Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002, 277: 36534-36543. 10.1074/jbc.M202605200.CrossRefPubMed Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K: Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002, 277: 36534-36543. 10.1074/jbc.M202605200.CrossRefPubMed
30.
go back to reference Torigoe T, Izumi H, Yoshida Y, Ishiguchi H, Okamoto T, Itoh H, Kohno K: Low pH enhances Sp1 DNA binding activity and interaction with TBP. Nucleic Acids Res. 2003, 31: 4523-4530. 10.1093/nar/gkg487.PubMedCentralCrossRefPubMed Torigoe T, Izumi H, Yoshida Y, Ishiguchi H, Okamoto T, Itoh H, Kohno K: Low pH enhances Sp1 DNA binding activity and interaction with TBP. Nucleic Acids Res. 2003, 31: 4523-4530. 10.1093/nar/gkg487.PubMedCentralCrossRefPubMed
31.
go back to reference De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S: Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007, 67: 5408-17. 10.1158/0008-5472.CAN-06-4095.CrossRefPubMed De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S: Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007, 67: 5408-17. 10.1158/0008-5472.CAN-06-4095.CrossRefPubMed
32.
go back to reference Thamm DH, Vail DM: Mast cell tumors. Small Animal Clinical Oncology. Edited by: Withrow SJ, MacEwen EG. 2007, Philadelphia, PA: WB Saunders Co, 402-424. 4CrossRef Thamm DH, Vail DM: Mast cell tumors. Small Animal Clinical Oncology. Edited by: Withrow SJ, MacEwen EG. 2007, Philadelphia, PA: WB Saunders Co, 402-424. 4CrossRef
33.
go back to reference Brooks D, Watson GL: Omeprazole in a dog with gastrinoma. J Vet Intern Med. 1997, 11: 379-381. 10.1111/j.1939-1676.1997.tb00485.x.CrossRefPubMed Brooks D, Watson GL: Omeprazole in a dog with gastrinoma. J Vet Intern Med. 1997, 11: 379-381. 10.1111/j.1939-1676.1997.tb00485.x.CrossRefPubMed
34.
go back to reference Fukushima R, Ichikawa K, Hirabayashi M, Yamagami T, Koyama H, Hirose H, Uchino T: A case of canine gastrinoma. J Vet Med Sci. 2004, 66: 993-995. 10.1292/jvms.66.993.CrossRefPubMed Fukushima R, Ichikawa K, Hirabayashi M, Yamagami T, Koyama H, Hirose H, Uchino T: A case of canine gastrinoma. J Vet Med Sci. 2004, 66: 993-995. 10.1292/jvms.66.993.CrossRefPubMed
35.
go back to reference Hughes SM: Canine gastrinoma: a case study and literature review of therapeutic options. N Z Vet J. 2006, 54: 242-247. 10.1080/00480169.2006.36705.CrossRefPubMed Hughes SM: Canine gastrinoma: a case study and literature review of therapeutic options. N Z Vet J. 2006, 54: 242-247. 10.1080/00480169.2006.36705.CrossRefPubMed
36.
go back to reference Ward CR: Gastrointestinal endocrine disease. Edited by: Ettinger SJ, Feldman EC. 2010, Textbook of Veterinary Internal Medicine, 1862-1865. Saunders, St. Louis, Seventh Ward CR: Gastrointestinal endocrine disease. Edited by: Ettinger SJ, Feldman EC. 2010, Textbook of Veterinary Internal Medicine, 1862-1865. Saunders, St. Louis, Seventh
37.
go back to reference Klohs WD, Steinkampf RW: The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol. 1988, 34: 180-185.PubMed Klohs WD, Steinkampf RW: The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol. 1988, 34: 180-185.PubMed
38.
go back to reference Simon SM, Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 1994, 91: 3497-3504. 10.1073/pnas.91.9.3497.PubMedCentralCrossRefPubMed Simon SM, Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 1994, 91: 3497-3504. 10.1073/pnas.91.9.3497.PubMedCentralCrossRefPubMed
39.
go back to reference Coruzzi G, Adami M, Bertaccini G: Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole. Gen Pharmacol. 1995, 26: 1027-1032. 10.1016/0306-3623(94)00278-U.CrossRefPubMed Coruzzi G, Adami M, Bertaccini G: Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole. Gen Pharmacol. 1995, 26: 1027-1032. 10.1016/0306-3623(94)00278-U.CrossRefPubMed
40.
go back to reference Spugnini EP, Citro G, Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010, 29: 44-10.1186/1756-9966-29-44.PubMedCentralCrossRefPubMed Spugnini EP, Citro G, Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010, 29: 44-10.1186/1756-9966-29-44.PubMedCentralCrossRefPubMed
41.
go back to reference Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H, Uchida A: Acridine orange used for photodynamic therapy accumulates in malignantmusculoskeletal tumors depending on pH gradient. Anticancer Res. 2006, 26: 187-193.PubMed Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H, Uchida A: Acridine orange used for photodynamic therapy accumulates in malignantmusculoskeletal tumors depending on pH gradient. Anticancer Res. 2006, 26: 187-193.PubMed
42.
go back to reference Kusuzaki K, Murata H, Matsubara T, Satonaka H, Wakabayashi T, Matsumine A, Uchida A: Acridine orange could be an innovative anticancer agent under photon energy. In Vivo. 2007, 21: 205-214.PubMed Kusuzaki K, Murata H, Matsubara T, Satonaka H, Wakabayashi T, Matsumine A, Uchida A: Acridine orange could be an innovative anticancer agent under photon energy. In Vivo. 2007, 21: 205-214.PubMed
43.
go back to reference Fais S: Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010, 267 (5): 515-25. 10.1111/j.1365-2796.2010.02225.x.CrossRefPubMed Fais S: Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010, 267 (5): 515-25. 10.1111/j.1365-2796.2010.02225.x.CrossRefPubMed
44.
go back to reference Abraham J, Ross E, Klickovich RJ: Cancer-related bone pain. Edited by: Ballantyne J, Fishman SM, Rathmell JP. 2009, Bonica's management of pain. Lippincott Williams & Wilkins, 629-654. 4 Abraham J, Ross E, Klickovich RJ: Cancer-related bone pain. Edited by: Ballantyne J, Fishman SM, Rathmell JP. 2009, Bonica's management of pain. Lippincott Williams & Wilkins, 629-654. 4
45.
go back to reference Drochioiu G: Chronic metabolic acidosis may be the cause of cachexia: body fluid pH correction may be an effective therapy. Med Hypotheses. 2008, 70: 1167-73. 10.1016/j.mehy.2007.11.007.CrossRefPubMed Drochioiu G: Chronic metabolic acidosis may be the cause of cachexia: body fluid pH correction may be an effective therapy. Med Hypotheses. 2008, 70: 1167-73. 10.1016/j.mehy.2007.11.007.CrossRefPubMed
46.
go back to reference Pan HL, Zhang YQ, Zhao ZQ: Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol Pain. 2010, 6: 85-10.1186/1744-8069-6-85.PubMedCentralCrossRefPubMed Pan HL, Zhang YQ, Zhao ZQ: Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol Pain. 2010, 6: 85-10.1186/1744-8069-6-85.PubMedCentralCrossRefPubMed
47.
go back to reference Okumura R, Shima K, Muramatsu T, Nakagawa K, Shimono M, Suzuki T, Magloire H, Shibukawa Y: The odontoblast as a sensory receptor cell? The expression of TRPV1 (VR-1) channels. Arch Histol Cytol. 2005, 68: 251-257. 10.1679/aohc.68.251.CrossRefPubMed Okumura R, Shima K, Muramatsu T, Nakagawa K, Shimono M, Suzuki T, Magloire H, Shibukawa Y: The odontoblast as a sensory receptor cell? The expression of TRPV1 (VR-1) channels. Arch Histol Cytol. 2005, 68: 251-257. 10.1679/aohc.68.251.CrossRefPubMed
48.
go back to reference Roodman GD: Biology of Osteoclast Activation in Cancer. J Clin Oncol. 2001, 19: 3562-3571.PubMed Roodman GD: Biology of Osteoclast Activation in Cancer. J Clin Oncol. 2001, 19: 3562-3571.PubMed
49.
go back to reference Porrello A, Cardelli P, Spugnini EP: Pet models in cancer research: general principles. J Exp Clin Canc Res. 2004, 2: 5-17. Porrello A, Cardelli P, Spugnini EP: Pet models in cancer research: general principles. J Exp Clin Canc Res. 2004, 2: 5-17.
50.
go back to reference Porrello A, Cardelli P, Spugnini EP: Oncology of companion animals as a model for humans: an overview of tumor histotypes. J Exp Clin Cancer Res. 2006, 25: 97-106.PubMed Porrello A, Cardelli P, Spugnini EP: Oncology of companion animals as a model for humans: an overview of tumor histotypes. J Exp Clin Cancer Res. 2006, 25: 97-106.PubMed
Metadata
Title
Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
Authors
Enrico P Spugnini
Alfonso Baldi
Sabrina Buglioni
Francesca Carocci
Giulia Milesi de Bazzichini
Gianluca Betti
Ilaria Pantaleo
Francesco Menicagli
Gennaro Citro
Stefano Fais
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-221

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine